The Evolving Role of India as a Talent Hub for Healthcare R&D

In an interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Suneela Thatte, VP and Head – Healthcare R&D for India, Merck KGaA, shares India’s transition from a cost-driven support hub to a strategic R&D innovator. She highlights the evolving capabilities, global integration, talent development, and the need for sustained collaboration to achieve leadership in healthcare innovation. Suneela Thatte, a seasoned leader with over 28 years of experience, specializing in clinical research, R&D operations, business strategy, and policy advocacy, driving global research excellence, talent development, and industry collaboration across India’s healthcare ecosystem.

With India’s growing pool of scientific and clinical talent, how is the country transitioning from cost-efficient support roles to leading high-value healthcare R&D and innovation programs?

India’s journey in pharma R&D has evolved over three decades, and it can be said with conviction that the narrative is changing. For a long time, our role was defined by cost efficiency, and our scope was limited to support functions, back-end analytics, and regulatory documentation. However, today it shows a clear shift. While on one side, Indian teams are executing complex tasks, they are also contributing to decision-making. In many Global Capability Centers, scientists and clinicians are now influencing research priorities, designing studies, and contributing to therapeutic strategy.

What drives this transition is a quiet, earned confidence. Multinational companies are not here because India is affordable; they are here because Indian scientists have proven, repeatedly, that they belong at the center of the conversation.

That said, India is still building its presence in discovery and innovation and the trajectory is promising. The next step is to move beyond support functions, and this requires more than industry effort; it needs long-term collaboration between government, academia, healthcare institutions, and the private sector.

The Biopharma SHAKTI Scheme and the strengthening of NIPERs as centers of excellence are critical initiatives. If we can align training programs with industry needs, foster academia-industry partnerships, and sustain investment in emerging areas like biologics and digital health, India will be well placed to take on complex R&D mandates.

The vision we should pursue is not incremental. We want to see an Indian scientist leading a global first-in-class program - not as a delegate, but as the principal. We want a therapy discovered in Hyderabad or Pune to reach a patient in Sao Paulo or Stockholm. That is the scale of ambition this generation of Indian researchers is capable of, and it is the responsibility of industry, government, and academia to build the conditions that make it possible. That, in my view, is not just exciting - it is urgent.

As global pharma and biotech firms expand R&D Centers in India, what specific capabilities are driving this shift toward more complex research ownership and innovation mandates?The conversation around India’s role in global healthcare R&D has become far more strategic over the last few years. What we are seeing today is not simply an expansion of R&D presence, but a deeper integration of Indian teams into core scientific decision making and innovation agendas. For global pharma and biotech companies, India is increasingly being viewed as a place where complex research problems can be solved collaboratively and at scale. What makes this evolution especially significant is the nature of the capabilities now emerging from India, and the impact they are beginning to have far beyond scientific operations.

The capabilities driving this change matter not just as technical competencies, but because of what they make possible for patients. When Indian teams apply computational biology to model disease pathways, they are accelerating timelines that can mean years of life for people waiting for answers.

Many GCCs today support a significant share of global work across drug development, regulatory operations, pharmacovigilance, and data management. Teams from India are not just managing operations, but shaping research priorities, designing studies, and enabling faster, more integrated collaboration with global counterparts.

For giving a clear example, we at Merck see this evolution firsthand. Our Healthcare R&D India Hub is deeply embedded in the global R&D network- whether it’s pharmacovigilance, scientific communications, regulatory support, or knowledge?sharing across functions.

Also Read: How Portfolio Strategy Drives Profitability in Pharma Markets

With increasing demand for specialized skills in areas like biologics, genomics, and clinical data science, how is India addressing emerging talent gaps in advanced healthcare research?

The skills required for advanced healthcare R&D are evolving faster than most training systems can follow - and that gap has a human face. There are thousands of exceptionally capable young scientists in India who have the aptitude for biologics, genomics, and AI-driven discovery, but lack structured pathways into these disciplines. That is not a market inefficiency. It is a missed opportunity that the entire ecosystem - industry, government, and academia - has a collective obligation to close. India's talent base is not the constraint; our investment in translating that potential into specialized expertise is.

Encouragingly, steps are being taken to bridge this gap. The Biopharma SHAKTI mission is a major push to strengthen capabilities in biologics and data?driven innovation, while institutions like the NIPERs are expanding their role in building industry?ready talent and fostering closer academia?industry collaboration.

Industry too is playing its part. Companies are investing in internal academies, co?developed curricula, and academic partnerships. At Merck, we launched the Catalyst Program precisely because we believe the best investment a company can make is in someone's first serious encounter with science. This is a three-month immersive program where high-potential pharmacy students have an opportunity to learn about the latest trends in R&D, therefore making themselves better prepared for the industry.

India has already proven its scientific strength- the next leap is about converting that strength into leadership through consistent talent development.

As cross-border collaborations intensify, how are Indian R&D teams integrating with global innovation ecosystems while maintaining speed, quality, and regulatory alignment?

R&D today is far more continuous and interconnected than it was a decade ago. Today, our teams in India are embedded in global innovation ecosystems, contributing not just to execution but to problem?solving, product thinking, and specialized research initiatives. What makes this possible is a combination of deep technical talent, engineering maturity, and growing confidence from global partners in India’s ability to deliver complex work at scale.

Digital infrastructure has been a decisive catalyst. Cloud?based environments, AI?enabled analytics, and real?time collaboration tools allow distributed teams to interrogate the same datasets, co?author publications, and participate in decision?making forums with true parity. The speed and quality of output are no longer constrained by geography- Indian teams are working shoulder?to?shoulder with peers from across the world.  

The question of where decisions are made, I believe, does not matter. The more important question is whose thinking shapes the decision — and on that measure, the shift is real and accelerating.

Also Read: Building Sustainable Pharma Growth through Ethical Marketing Practices 

With rising competition from other emerging markets, what structural advantages and constraints define India’s long-term positioning as a healthcare R&D talent hub?

Over the years, India has built a solid foundation in healthcare R&D. The scale of our life sciences talent pool, a strong pharmaceutical manufacturing base, and the diversity of our patient population provide distinct advantage in clinical research and drug development. Combined with a growing healthcare startup ecosystem and decades of operational experience, these strengths position India well to play a larger role in global innovation.

The real risk is not that another country outpaces us, but it is that we underestimate ourselves and design modest ambitions to match. India's answer to a competitive world is to lead on the things only India can offer, and to do that with conviction. Supply chain dependence, particularly around critical APIs, is one area where we must build greater self?reliance. Similarly, in cutting?edge domains like gene therapy and advanced biologics, the ecosystem will need sharper focus and sustained investment to stay ahead.

India’s long?term role will be defined not by scale alone, but by how consistently we build differentiated capabilities and earn global trust. The opportunity is real and the trajectory is strong. What reassures me here is the growing alignment across industry, academia, and government- because when that kind of ecosystem matures with sustained intent, India can become indispensable to how global healthcare R&D is designed, delivered, and accelerated.

Looking ahead, how will India’s role evolve from a talent provider to a global innovation leader in healthcare R&D, and what investments will be critical to enable this transition?

In my view, India’s next chapter in healthcare R&D will be defined by how well we get our talent to think about and adopt innovation. The shift is already visible- teams here are contributing to discovery research, translational science, digital health, and AI?enabled R&D, not just execution.

What gives me confidence is the blend of scientific depth, clinical exposure, and digital capability, delivered at scale. I’ve seen collaborations between academia, hospitals, startups, and global pharma become more outcome?driven, and that integration is a strong signal of India’s trajectory.

I want to speak directly to the next generation of Indian scientists reading this: the infrastructure will improve, the policies will evolve, the investment will follow — but none of that will matter if you do not believe, deeply, that this field belongs to you as much as to anyone else in the world.

What lies ahead for India is not just a larger role in healthcare R&D, but a more defining one. The real shift will happen when India is recognized not only for the scale of its talent, but for the originality of its science, the strength of its innovation ecosystem, and its ability to solve some of healthcare’s most complex global challenges.

If we continue to invest with intent, in people, partnerships, infrastructure, and scientific ambition, India will move from contributing to the future of healthcare R&D to actively shaping where that future goes.